|
WO2003018563A1
(en)
|
2001-08-31 |
2003-03-06 |
Northwestern University |
Anti-inflammatory and protein kinase inhibitor composition and method of use
|
|
DE102004010194A1
(de)
*
|
2004-03-02 |
2005-10-13 |
Aventis Pharma Deutschland Gmbh |
4-Benzimidazol-2-yl-pyridazin-3-on-Derivate, ihre Herstellung und Verwendung in Arzneimitteln
|
|
DE102004010207A1
(de)
*
|
2004-03-02 |
2005-09-15 |
Aventis Pharma S.A. |
Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
|
|
EP1604988A1
(en)
|
2004-05-18 |
2005-12-14 |
Sanofi-Aventis Deutschland GmbH |
Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
|
|
EP1598348A1
(en)
|
2004-05-18 |
2005-11-23 |
Aventis Pharma Deutschland GmbH |
Novel pyridazinone derivatives as inhibitors of CDK2
|
|
EP1807085B1
(en)
|
2004-09-20 |
2013-08-21 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
|
|
US7829712B2
(en)
|
2004-09-20 |
2010-11-09 |
Xenon Pharmaceuticals Inc. |
Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
|
|
CA2580762A1
(en)
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as therapeutic agents
|
|
AR051091A1
(es)
|
2004-09-20 |
2006-12-20 |
Xenon Pharmaceuticals Inc |
Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
|
|
EP2289510A1
(en)
|
2004-09-20 |
2011-03-02 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
|
|
AU2005286648A1
(en)
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
|
|
CA2580857A1
(en)
|
2004-09-20 |
2006-09-28 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
|
|
JP5337375B2
(ja)
|
2004-11-02 |
2013-11-06 |
ノースウェスタン ユニバーシティ |
ピリダジン化合物、組成物および方法
|
|
CA2589102C
(en)
|
2004-11-02 |
2013-08-13 |
Northwestern University |
Pyridazine compounds and methods for using the compounds to treat inflammatory diseases
|
|
AU2006343359A1
(en)
|
2005-06-03 |
2007-11-15 |
Xenon Pharmaceuticals Inc. |
Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
|
|
EP1928437A2
(en)
|
2005-08-26 |
2008-06-11 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
|
EP2258358A3
(en)
|
2005-08-26 |
2011-09-07 |
Braincells, Inc. |
Neurogenesis with acetylcholinesterase inhibitor
|
|
EP1940389A2
(en)
|
2005-10-21 |
2008-07-09 |
Braincells, Inc. |
Modulation of neurogenesis by pde inhibition
|
|
US20070112017A1
(en)
|
2005-10-31 |
2007-05-17 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
WO2007127475A2
(en)
*
|
2006-04-28 |
2007-11-08 |
Northwestern University |
Pyridazines for demyelinating diseases and neuropathic pain
|
|
BRPI0710938A2
(pt)
|
2006-04-28 |
2012-06-26 |
Univ Northwestern |
formulações contendo compostos de piridazina para o tratamento de doenças neuroinflamatórias
|
|
CA2650711A1
(en)
|
2006-04-28 |
2007-11-08 |
Northwestern University |
Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
|
|
AU2007249399A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
|
JP2010500300A
(ja)
|
2006-08-08 |
2010-01-07 |
サノフィ−アベンティス |
アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
|
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
CN101538245B
(zh)
|
2008-03-18 |
2011-02-16 |
中国科学院上海药物研究所 |
一类哒嗪酮类化合物及其制备方法和制备药物的用途
|
|
US9212146B2
(en)
|
2008-03-18 |
2015-12-15 |
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences |
Substituted pyridazinones for the treatment of tumors
|
|
WO2010003624A2
(en)
|
2008-07-09 |
2010-01-14 |
Sanofi-Aventis |
Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
|
|
WO2010068601A1
(en)
|
2008-12-08 |
2010-06-17 |
Sanofi-Aventis |
A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
|
|
WO2010099217A1
(en)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
|
UA103918C2
(en)
*
|
2009-03-02 |
2013-12-10 |
Айерем Элелси |
N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
|
|
AU2012203023C1
(en)
*
|
2009-03-02 |
2013-11-07 |
Novartis Ag |
N-(hetero)aryl, 2- (hetero)aryl-substituted acetamides for use as Wnt signaling modulators
|
|
MX2012001729A
(es)
|
2009-08-26 |
2012-06-13 |
Sanofi Sa |
Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
|
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
WO2011157827A1
(de)
|
2010-06-18 |
2011-12-22 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
|
UY33469A
(es)
*
|
2010-06-29 |
2012-01-31 |
Irm Llc Y Novartis Ag |
Composiciones y metodos para modular la via de señalizacion de wnt
|
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
|
EP2683702B1
(de)
|
2011-03-08 |
2014-12-24 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
US8871758B2
(en)
|
2011-03-08 |
2014-10-28 |
Sanofi |
Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
|
EP2683698B1
(de)
|
2011-03-08 |
2017-10-04 |
Sanofi |
Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
US8828995B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
|
US8895547B2
(en)
|
2011-03-08 |
2014-11-25 |
Sanofi |
Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
|
|
EP2683699B1
(de)
|
2011-03-08 |
2015-06-24 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
EP2683701B1
(de)
|
2011-03-08 |
2014-12-24 |
Sanofi |
Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
EP2683705B1
(de)
|
2011-03-08 |
2015-04-22 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
WO2012120052A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
EP2760862B1
(en)
|
2011-09-27 |
2015-10-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
GB201201100D0
(en)
*
|
2012-01-20 |
2012-03-07 |
Medical Res Council |
Polypeptides and methods
|
|
EP3290407B1
(en)
|
2013-10-18 |
2020-01-01 |
Celgene Quanticel Research, Inc |
Bromodomain inhibitors
|
|
KR102319882B1
(ko)
*
|
2014-02-19 |
2021-11-03 |
아비브 테라퓨틱스, 인크. |
암의 치료를 위한 폴리사이클릭 아미드와 결합하는 미토콘드리아 알데히드 탈수소효소 2 (aldh2) 및 그의 용도
|
|
CA3025227A1
(en)
|
2016-05-25 |
2017-11-30 |
Bayer Pharma Aktiengesellschaft |
3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
|
|
JP7128826B2
(ja)
*
|
2017-02-09 |
2022-08-31 |
バイエル・アクチエンゲゼルシヤフト |
がん治療のための２－ヘテロアリール－３－オキソ－２，３－ジヒドロピリダジン－４－カルボキサミド類
|
|
EP3713922A1
(en)
*
|
2017-11-21 |
2020-09-30 |
Bayer Aktiengesellschaft |
Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides
|
|
KR102919209B1
(ko)
|
2018-08-10 |
2026-01-28 |
다이아핀 테라퓨틱스, 엘엘씨 |
트리-펩타이드 그리고 대사, 심장혈관 및 염증성 장애의 치료
|
|
CN111533697B
(zh)
*
|
2020-05-07 |
2023-03-31 |
成都大学 |
4-氨基哒嗪酮类化合物及其制备方法
|
|
CN111393374A
(zh)
*
|
2020-05-08 |
2020-07-10 |
张建蒙 |
氧代二氢哒嗪类衍生物及其在抗肿瘤药物中的应用
|
|
CN111533735A
(zh)
*
|
2020-05-08 |
2020-08-14 |
张建蒙 |
氧代二氢哒嗪噻唑类衍生物及其在抗肿瘤药物中的应用
|
|
WO2022113003A1
(en)
|
2020-11-27 |
2022-06-02 |
Rhizen Pharmaceuticals Ag |
Cdk inhibitors
|
|
WO2022149057A1
(en)
|
2021-01-05 |
2022-07-14 |
Rhizen Pharmaceuticals Ag |
Cdk inhibitors
|
|
AU2022271290A1
(en)
|
2021-05-07 |
2023-11-23 |
Kymera Therapeutics, Inc. |
Cdk2 degraders and uses thereof
|